CareLit · DOI-Nachweis · Klinische Pädiatrie
Impact of imatinib on in vitro osteoclastogenic differentiation of monocytes in children and adolescents with chronic myeloid leukemia.
DOI 10.1055/s-0029-1222646
Bibliografische Angaben
Nachweis in CareLit
Autor:innenB Jaeger, J Lohse, K Navratiel, A Rösen-Wolff, M Suttorp
ZeitschriftKlinische Pädiatrie
Ausgabe05/2009
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: The tyrosine kinase (TK) inhibitor imatinib (IMA) has dramatically improved the treatment results of chronic myeloid leukemia (CML) via blockade of the constitutively activated TK bcr-abl. However, IMA also inhibits other TKs like PDGFR-alpha and -beta and c-FMS, thus exerting a negative impact on the differentiation and proliferation of osteoclasts and osteoblasts. As a net result, disturbances of bone…
Zitieren
Zitierempfehlung
B Jaeger, J Lohse, K Navratiel, A Rösen-Wolff, M Suttorp (2009) Impact of imatinib on in vitro osteoclastogenic differentiation of monocytes in children and adolescents with chronic myeloid leukemia. Klinische Pädiatrie (05). https://doi.org/10.1055/s-0029-1222646
Mit CareLit weiterarbeiten